Affimed Stock Price, News & Analysis

Affimed N.V. (AFMD) is a clinical-stage immuno-oncology company that has focused on harnessing the innate immune system to fight cancer. According to company disclosures, Affimed develops innate cell engagers (ICE®) designed to enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. These ICE® molecules are generated on the company’s proprietary ROCK® platform, which is described as predictably generating customized molecules that leverage the power of innate immune cells to destroy tumor cells. Affimed has stated that a number of ICE® molecules are in clinical development, being studied as mono- or combination therapy.

The company has been listed on Nasdaq under the ticker AFMD, but a Form 25 filed with the U.S. Securities and Exchange Commission on July 21, 2025, indicates that its common stock has been removed from listing on The Nasdaq Stock Market LLC. In May 2025, Affimed announced that it had filed for insolvency proceedings with the local court of Mannheim in Germany and that Nasdaq staff determined trading of its common shares would be suspended and a notification of delisting would be filed. These developments mean that AFMD represents a company undergoing insolvency proceedings and delisting, and investors researching the symbol should consider it in that historical and restructuring context.

Affimed reports that it is headquartered in Mannheim, Germany. Its stated vision is to give patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s approach centers on engaging innate immune effector cells to attack tumor cells through antibody-mediated mechanisms.

Innate Cell Engager (ICE®) Platform

Affimed’s ICE® molecules are described as bispecific, tetravalent antibodies that bind to targets on innate immune cells and tumor cells. By doing so, they are intended to enable tumor cell killing in hematologic malignancies and solid tumors. The company states that these ICE® molecules are generated using its ROCK® platform, which is characterized as a fit-for-purpose technology that predictably generates customized molecules to leverage innate immune cells for tumor cell destruction.

Affimed has highlighted several ICE® programs in clinical development. These programs are being evaluated as monotherapies and in combination with other agents in indications such as non-small cell lung cancer (NSCLC) and acute myeloid leukemia (AML), based on company news releases describing clinical and early efficacy data.

Selected Clinical Programs

AFM24 is described by Affimed as a tetravalent, bispecific ICE® that activates the innate immune system by binding to CD16A on innate immune cells and to epidermal growth factor receptor (EGFR), a protein widely expressed on solid tumors. According to Affimed, AFM24 uses EGFR as a docking site to engage innate immune cells for tumor cell killing through antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. AFM24 is being studied in advanced or metastatic NSCLC, including in combination with the checkpoint inhibitor atezolizumab, with company communications reporting exposure–response analyses and clinical activity in heavily pretreated NSCLC populations.

AFM28 is another ICE® program described by Affimed as a tetravalent, bispecific CD123- and CD16A-binding ICE® designed for patients with acute myeloid leukemia (AML). The company states that AFM28 engages natural killer cells to initiate leukemic cell killing via antibody-dependent cellular cytotoxicity, even at low CD123 expression levels. AFM28 is reported to be in a first-in-human Phase 1 study in relapsed/refractory AML, with Affimed disclosing early data on composite complete remission rates and safety.

Affimed has also referenced an ICE® program known as acimtamig (AFM13), evaluated in combination with AlloNK® (AB-101) in relapsed or refractory classical Hodgkin lymphoma in the LuminICE-203 study, based on an abstract accepted for oral presentation at a major oncology conference.

Corporate Status and Delisting

On May 13, 2025, Affimed announced that it had filed an application for the opening of insolvency proceedings with the local court of Mannheim in Germany, stating that the company and its subsidiary Affimed GmbH were overindebted under German law and that their liquidity condition raised substantial doubt about their ability to continue as a going concern. The company reported that the insolvency filing and resulting proceedings would result in its common shares being suspended from trading on, and subsequently delisted from, The Nasdaq Global Market.

On May 14, 2025, Affimed disclosed that Nasdaq staff had notified the company that trading of its common shares would be suspended at the opening of business on May 20, 2025, and that a Form 25 Notification of Delisting would be filed with the SEC to delist the company’s securities from Nasdaq. The company stated that it did not expect to appeal this determination. The Form 25 filed on July 21, 2025, identifies Affimed N.V. as the issuer and confirms the removal of its common stock from listing and registration on The Nasdaq Stock Market LLC.

Research Focus and Indications

Affimed’s disclosures emphasize a focus on hematologic malignancies and solid tumors. In hematologic cancers, AFM28 is being evaluated in relapsed/refractory AML, and acimtamig (AFM13) has been studied in classical Hodgkin lymphoma in combination with an allogeneic NK cell therapy. In solid tumors, AFM24 is being developed for NSCLC, including EGFR wild-type and EGFR mutant NSCLC, and has been studied in combination with atezolizumab.

The company’s communications describe its ICE® approach as a way to use innate immune cells to provide a tumor-targeted immunotherapy option. Clinical updates released by Affimed have discussed response rates, disease control rates, progression-free survival, and safety profiles in the context of early- and mid-stage clinical trials, as well as exposure–response analyses intended to inform dose optimization.

Headquarters and Sector Classification

Affimed reports that it is headquartered in Mannheim, Germany. In industry classification terms, it operates in the pharmaceutical preparation manufacturing space within the broader manufacturing sector, with a specific focus on clinical-stage biopharmaceutical research and development in immuno-oncology.

Investor Considerations

For investors researching AFMD, it is important to note that Affimed has filed for insolvency proceedings in Germany and that its common stock has been delisted from Nasdaq following the suspension of trading and the filing of Form 25. Company statements emphasize that there can be no assurance as to the outcome of preliminary or formal insolvency proceedings or whether the company will emerge as a going concern. Historical SEC filings, press releases, and clinical data updates provide context on the company’s ICE® platform, clinical programs, and prior listing status.

Frequently Asked Questions (FAQ)

• What does Affimed N.V. do?
  

  Affimed N.V. is described as a clinical-stage immuno-oncology company that develops innate cell engagers (ICE®) to enable a tumor-targeted approach to recognize and kill hematologic and solid tumors. Its ICE® molecules are generated on the proprietary ROCK® platform.

• What is Affimed’s ICE® technology?
  

  ICE® molecules are bispecific, tetravalent antibodies that bind to targets on innate immune cells and tumor cells. According to Affimed, this design allows innate immune cells to recognize and kill tumor cells through antibody-dependent mechanisms.

• What is the ROCK® platform?
  

  Affimed describes its ROCK® platform as a proprietary, fit-for-purpose technology that predictably generates customized ICE® molecules. These molecules are intended to leverage the power of innate immune cells to destroy tumor cells.

• What are AFM24 and AFM28?
  

  AFM24 is a tetravalent, bispecific ICE® that binds CD16A on innate immune cells and EGFR on tumor cells to promote tumor cell killing. AFM28 is a tetravalent, bispecific CD123- and CD16A-binding ICE® designed for patients with acute myeloid leukemia, engaging NK cells to kill leukemic cells via antibody-dependent cellular cytotoxicity.

• Which cancer indications has Affimed highlighted?
  

  Affimed has reported clinical work in non-small cell lung cancer with AFM24, including combinations with atezolizumab, in acute myeloid leukemia with AFM28, and in classical Hodgkin lymphoma with acimtamig (AFM13) in combination with AlloNK® (AB-101), based on accepted conference abstracts and company updates.

• Where is Affimed headquartered?
  

  Affimed states that it is headquartered in Mannheim, Germany.

• What is Affimed’s stock symbol and listing status?
  

  Affimed’s common shares have traded under the symbol AFMD on Nasdaq. However, a Nasdaq delisting notice and a Form 25 filed on July 21, 2025, indicate that its common stock has been removed from listing and registration on The Nasdaq Stock Market LLC.

• What happened to AFMD on Nasdaq?
  

  In May 2025, Affimed announced that it filed for insolvency in Germany and that Nasdaq staff determined trading of its common shares would be suspended and a Form 25 would be filed to delist the securities. The Form 25 confirms removal of its common stock from Nasdaq listing and registration.

• Is Affimed in insolvency proceedings?
  

  Affimed reported on May 13, 2025, that it had filed for the opening of ordinary insolvency proceedings over its assets with the local court of Mannheim in Germany, stating that the company and Affimed GmbH were overindebted and that their liquidity condition raised substantial doubt about their ability to continue as a going concern.

• Does Affimed still operate as a going concern?
  

  Affimed has stated that there can be no assurance as to the outcome of preliminary or formal insolvency proceedings or as to whether the company or Affimed GmbH will emerge from insolvency as a going concern. This uncertainty is part of the company’s own disclosures.